A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Launched by IMMUNE RESPONSE BIOPHARMA, INC. · May 28, 2014

Keywords

ClinConnect Summary

The primary objective is to compare between treatment groups the Measures of neurologic disability EDSS scores.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ages Eligible for Study: 18 Years to 70 Years
• • Genders Eligible for Study: Both
• • Accepts Healthy Volunteers: No Criteria
• • Subject is between 18 and 70 years of age, inclusive.
• • Definite MS by the revised McDonald criteria (2005) (Appendix A), with a Secondary Progressive course.
• • Expanded Disability Status Scale (EDSS) \>=score 3.5 (Appendix B).
• • Two or more documented clinical relapses of MS in the preceding 24 months OR one documented clinical relapse of MS in the preceding 1 2 months prior to screening .
• * Laboratory values within the following limits:
• • Creatinine 1 . 5 x high normal.
• • Hemoglobin
• Exclusion Criteria:
• • Subjects currently prescribed Campath or Lemtrada